GRAL
NASDAQ HealthcareGRAIL, Inc. - Common Stock
Diagnostics & Research
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
�� 市场数据
| 价格 | $51.71 |
|---|---|
| 成交量 | 730,329 |
| 市值 | 2.12B |
| RSI（14日） | 55.3 |
| 200日均线 | $66.27 |
| 50日均线 | $59.69 |
| 52周最高 | $118.84 |
| 52周最低 | $26.05 |
| Forward P/E | -6.14 |
| Price / Book | 0.81 |
🎯 投资策略评分
GRAL 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🔪 Falling Knife (92/100) — 此策略 逆向投资（超卖 + 低于移动均线）.
评分最低的策略： 🚀 Moon Shot (14/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 GRAL in your text
粘贴任何文章、记录或帖子 — 工具将提取 GRAL 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.